SpringerLink
Log in

New routes in the polycystic ovary syndrome labyrinth: A way out?

  • Conclusion
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Franks S. Polycystic ovary syndrome. N. Engl. J. Med. 333: 853, 1995.

    Article  PubMed  CAS  Google Scholar 

  2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18: 774, 1997.

    PubMed  CAS  Google Scholar 

  3. Zawadzky J.K., Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A. et al. (Eds.), Current issues in endocrinology and metabolism: polycystic ovary syndrome. Blackwell, Boston, 1992, pp. 377.

    Google Scholar 

  4. Givens J.R., Andersen R.N., Wiser W.L., Donelson A.J., Coleman S.A. A testosterone-secreting, gonadotropin-responsive pure thecoma and polycystic ovarian disease. J. Clin. Endocrinol. Metab. 41: 845, 1975.

    Article  PubMed  CAS  Google Scholar 

  5. Dewailly D., Vantyghem-Haudiquet M.C., Sainsard C., et al. Clinical and biological phenotypes in late-onset 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 63: 418, 1986.

    Article  PubMed  CAS  Google Scholar 

  6. Abbott D.H., Dumesic D.A., Eisner J.R., Kenmitz J.W., Goy R.W. The prenatally androgenized female rhesus monkey as a model for PCOS. In: Azziz R., Nestler J.E., Dewailly D. (Eds.), Androgen excess disorders in women. Lippincott-Raven, Philadelphia, 1997, p. 369.

    Google Scholar 

  7. Moghetti P., Tosi F., Castello R., et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J. Clin. Endocrinol. Metab. 81: 952, 1996.

    PubMed  CAS  Google Scholar 

  8. Weil S.J., Vendola K., Zhou J., et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J. Clin. Endocrinol. Metab. 83: 2479, 1998.

    Article  PubMed  CAS  Google Scholar 

  9. Billig H., Furuta I., Hsueh J.W. Estrogens inhibit and androgens enhance ovarian granulosa cell apoptosis. Endocrinology 133: 2204, 1993.

    PubMed  CAS  Google Scholar 

  10. Lachelin G.C.L., Barnett M., Hopper B.R., Brink G., Yen S.S.C. Adrenal function in normal women and women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 49: 892, 1979.

    Article  PubMed  CAS  Google Scholar 

  11. Yen S.S.C., Chaney C., Judd H.L. Functional aberrations of the hypothalamic-pituitary system in polycystic ovary syndrome. A consideration of the pathogenesis. In: James V.H., Serio M., Giusti G. (Eds.), The endocrine function of the human ovary. Academic Press, New York, 1976, p. 373.

    Google Scholar 

  12. Azziz R. Abnormalities of adrenocortical steroidogenesis in PCOS. In: Azziz R., Nestler J.E., Dewailly D. (Eds.), Androgen Excess Disorders in Women. Lippincott-Raven, Philadelphia, 1997, p. 403.

    Google Scholar 

  13. Moghetti P., Castello R., Negri C., et al. Insulin infusion amplifies 17α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J. Clin. Endocrinol. Metab. 81: 881, 1996.

    PubMed  CAS  Google Scholar 

  14. Rosenfield R.L. Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steroidogenesis and that hyperinsulinemia may be involved. J. Clin. Endocrinol. Metab. 81: 878, 1996.

    PubMed  CAS  Google Scholar 

  15. Ditkoff E.C., Fruzzetti F., Chang L., Stanczyk F.Z., Lobo R.A. The impact of estrogen on adrenal androgen sensitivity and secretion in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 80: 603, 1995.

    PubMed  CAS  Google Scholar 

  16. Casson P.R., Kristiansen S.B., Umstot E., et al. Ovarian hyperstimulation augments adrenal dehydroepiandrosterone sulfate secretion. Fertil. Steril. 65: 950, 1996.

    PubMed  CAS  Google Scholar 

  17. Barnes R.B., Rosenfield R.L., Burstein S., Ehrmann DA Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N. Engl. J. Med. 320: 559, 1989.

    Article  PubMed  CAS  Google Scholar 

  18. Ehrmann D.A., Barnes R.B., Rosenfield R.L. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr. Rev. 16: 322, 1995.

    Article  PubMed  CAS  Google Scholar 

  19. Dunaif A., Segal K.R., Futterweit W., Dobrjansky A. Profund peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165, 1989.

    Article  PubMed  CAS  Google Scholar 

  20. Ovesen P., Moller J., Ingerslev H.J., et al. Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 77: 1636, 1993.

    PubMed  CAS  Google Scholar 

  21. Holte J., Bergh T., Berne C., Berglund L., Lithell H. Enhanced insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J. Clin. Endocrinol. Metab. 78: 1052, 1994.

    PubMed  CAS  Google Scholar 

  22. Holte J., Bergh T., Berne C., Wide L., Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 80: 2586, 1995.

    PubMed  CAS  Google Scholar 

  23. Bjorntorp P. Abdominal obesity and the development of noninsulin-dependent diabetes mellitus. Diabetes Metab. Rev. 4: 615, 1988.

    Article  PubMed  CAS  Google Scholar 

  24. Ferrannini E., Barrett E.J., Bevilacqua S., DeFronzo R.A. Effect of fatty acids on glucose production and utilization in man. J. Clin. Invest. 72: 1737, 1983.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  25. Rodin A., Thakkar H., Yaylor N., Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11β-hydroxysteroid dehydrogenase. N. Engl. J. Med. 330: 460, 1994.

    Article  PubMed  CAS  Google Scholar 

  26. Lanzone A., Petraglia F., Fulghesu A.M., Ciampelli M., Caruso A., Mancuso S. Corticotropin-releasing hormone induces an exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome. Fertil. Steril. 63: 1195, 1995.

    PubMed  CAS  Google Scholar 

  27. Waterworth D.M., Bennet S.T., Gharani N., et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 349: 986, 1997.

    Article  PubMed  CAS  Google Scholar 

  28. Barbieri R.L., Makris A., Randall R.W., Daniels G., Kristner R.W., Ryan K.J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J. Clin. Endocrinol. Metab. 62: 904, 1986.

    Article  PubMed  CAS  Google Scholar 

  29. Nestler J.E., Powers L.P., Matt D.W. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 72: 83, 1991.

    Article  PubMed  CAS  Google Scholar 

  30. Velazquez E.M., Mendoza S., Hamer T., Sosa F., Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperan-drogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43: 647, 1994.

    Article  PubMed  CAS  Google Scholar 

  31. Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction in insulin secretion in polycystic ovary syndrome. N. Engl. J. Med. 335: 617, 1996.

    Article  PubMed  CAS  Google Scholar 

  32. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81: 3299, 1996.

    PubMed  CAS  Google Scholar 

  33. Ehrmann D.A., Schneider D.J., Sobel, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82: 2108, 1997.

    PubMed  CAS  Google Scholar 

  34. Nestler J.E., Jakubowicz D.J., Evans W.S., Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med. 338: 1876, 1998.

    Article  PubMed  CAS  Google Scholar 

  35. Dahlgren E., Janson P.O., Johansson S., Lapidus L., Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet. Gynecol. Scand. 71: 599, 1992.

    Article  PubMed  CAS  Google Scholar 

  36. Birdsall M.A., Farquhar C.M., White H.D. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann. Intern. Med. 126: 32, 1997.

    Article  PubMed  CAS  Google Scholar 

  37. Ibáñez L., Potau N., Virdis R., et al. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: Increased frequency of functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 76: 1599, 1993.

    PubMed  Google Scholar 

  38. Ibáñez L., Potau N., Zampolli M., Rique S., Saenger P., Carrascosa A. Hyperinsulinemia and decreased insulin-like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J. Clin. Endocrinol. Metab. 82: 2283, 1997.

    PubMed  Google Scholar 

  39. Ibáñez L., Potau N., Francois I., de Zegher F. Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J. Clin. Endocrinol. Metab. 1998 (in press).

  40. Donohue W.L., Uchida I. Leprechaunism: a euphemism for a rare familial disorder. J. Pediatr. 45: 505, 1954.

    Article  PubMed  CAS  Google Scholar 

  41. Barker D.J.P., Hales C.H.D., Osmond C., Clark P.M.S. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 36: 62, 1993.

    Article  PubMed  CAS  Google Scholar 

  42. Hofman P.L., Cutfield W.S., Robinson E.M., Bergman R.N., Menon R.K., Sperling M.A., Gluckman P.D. Insulin resistance in short children with intrauterine growth retardation. J. Clin. Endocrinol. Metab. 82: 402, 1997.

    PubMed  CAS  Google Scholar 

  43. Taylor A.E., McCourt B., Anderson E.J., et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 82: 2248, 1997.

    PubMed  CAS  Google Scholar 

  44. Rebar R., Judd H.L., Yen S.S.C., Rakoff J., Vandenberg G., Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J. Clin. Invest. 57: 1320, 1976.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  45. Pastor C.L., Griffin-Korf M.L., Aloi J.A., Evans W.S., Marshall J.C. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J. Clin. Endocrinol. Metab. 83: 582, 1998.

    PubMed  CAS  Google Scholar 

  46. Spinder T., Spijkstra J.J., Gooren L.J.G., Hompes P.G.A., van Kessel H. Effects of long-term testosterone administration on gonadotropin secretion in agonadal female to male transsexuals compared with hypogonadal and normal women. J. Clin. Endocrinol. Metab. 68: 200, 1989.

    Article  PubMed  CAS  Google Scholar 

  47. Sattar N., Hopkinson Z.O.C., Greer I.A. Insulin-sensitizing agents in polycystic ovary syndrome. Lancet 351: 305, 1998.

    Article  PubMed  CAS  Google Scholar 

  48. Adashi E.Y., Hsueh A.J.W., Yen S.C.C. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 108: 1441, 1981.

    Article  PubMed  CAS  Google Scholar 

  49. Toscano V., Adamo M.V., Caiola S., et al. Is hirsutism an evolving syndrome? J. Endocrinol. 97: 379, 1983.

    Article  PubMed  CAS  Google Scholar 

  50. Pasquali R., Antenucci D., Casimirri F., et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J. Clin. Endocrinol. Metab. 68: 173, 1989.

    Article  PubMed  CAS  Google Scholar 

  51. Prelevic G.M., Wurzburger M.I., Balint-Peric L., Nesic J.S. Inhibitory effect of sandostatin on luteinizing hormone and ovarian steroids in polycystic ovary syndrome. Lancet 336: 900, 1990.

    Article  PubMed  CAS  Google Scholar 

  52. Nestler J.E., Barlascini C.O., Matt D.W., et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 68: 1027, 1989.

    Article  PubMed  CAS  Google Scholar 

  53. Moghetti P., Castello R., Negri C., et al. Metformin effects on endocrine features, menstrual pattern and insulin sensitivity in polycystic ovary syndrome: a double blind, placebo-controlled study. Proc. 79th Annual Meeting of the Endocrine Society, Minneapolis, June 1997 (abstract).

  54. Inzucchi S.E., Maggs D.G., Spollet G.R., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med. 338: 867, 1998.

    Article  PubMed  CAS  Google Scholar 

  55. De Ziegler D., Steingold K., Cedars M., et al. Recovery of hormone secretion after chronic GnRH-agonist administration in women with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 68: 1111, 1989.

    Article  PubMed  Google Scholar 

  56. Christman G.M., Randolph J.F., Kelch R.P., Marshall J.C. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 72: 1278, 1991.

    Article  PubMed  CAS  Google Scholar 

  57. Godsland I.F., Walton C., Felton C., Proudler A., Patel A., Wynn V. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J. Clin. Endocrinol. Metab. 74: 64, 1992.

    PubMed  CAS  Google Scholar 

  58. Genazzani A.D., Petraglia F., Battaglia C., et al. A long-term treatment with gonadotropin-releasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the ovulatory function in patients with polycystic ovary syndrome. Fertil. Steril. 67: 463, 1997.

    Article  PubMed  CAS  Google Scholar 

  59. De Leo V., Lanzetta D., D’Antona D., La Marca A., Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83: 99, 1998.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolic Diseases, University of Verona, Verona, Italy

    Paolo Moghetti M.D. & R. Castello

Authors
  1. Paolo Moghetti M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Castello
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moghetti, P., Castello, R. New routes in the polycystic ovary syndrome labyrinth: A way out?. J Endocrinol Invest 21, 648–655 (1998). https://doi.org/10.1007/BF03350793

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03350793

Keywords

Search

Navigation